July 31, 2019 09:53 AM EDT

Atlantic Healthcare's drug fails late-stage test; Translate Bio breaks out early CF data

Natalie Grover

Reporter

→ Cambridge, UK-based Atlantic Healthcare disclosed that the late-stage program for its experimental drug, alicaforsen enema, has failed in patients with pouchitis, a progressive disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Atlantic Healthcare's drug fails late-stage test; Translate Bio breaks out early CF data

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

At­lantic Health­care's drug fails late-stage test; Trans­late Bio breaks out ear­ly CF da­ta

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Atlantic Healthcare's drug fails late-stage test; Translate Bio breaks out early CF data